UniQure leads genetic medicine biotech rally after news of Prasad’s exit
Source: BioPharma Dive - Latest News
Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many developers rose on the chance of a more industry-friendly successor.